인바디, 中 GLP-1 약국·병원 체중관리망 진입…빅파마 정체는 변수

InBody's partnership with a major pharmaceutical company in China's rapidly expanding GLP-1 obesity treatment market validates the company's clinical credibility and measurement precision, positioning it as a potential standard-bearer in weight management clinics and pharmacies. Beyond one-time equipment sales, the collaboration opens pathways to recurring revenue streams through software, maintenance, and data management services—a critical business model shift that could substantially improve profitability. If successfully scaled across China's pharmacy franchise networks and replicated internationally, this model could transform InBody from a device manufacturer into a clinical-grade healthcare solutions provider.